检索结果-南通市图书馆

Preoperational diagnosis and management of breast ductal carcinoma in situ arising within fibroadenoma:Two case reports

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2022年第11期10卷 3496-3504页

作者： Jun Wu Ke-Wang Sun Qiu-Ping Mo Ze-Ran Yang Yuan Chen Miao-Chun Zhong Department of Breast Surgery Zhejiang Provincial People’s HospitalPeople’s Hospital of Hangzhou Medical CollegeHangzhou 310014Zhejiang ProvinceChina Cancer Center Zhejiang Provincial People’s HospitalPeople’s Hospital of Hangzhou Medical CollegeHangzhou 310014Zhejiang ProvinceChina Department of Pathology Zhejiang Provincial People’s Hospital

BACKGROUND ductal carcinoma in situ(DCIS)arising within fibroadenoma is a type of tumor that is rarely encountered in clinic,with only about 100 cases of carcinoma arising within a fibroadenoma reported in the ***,we present two cases of breast DCIS arising within a fibroadenoma and discuss their clinical and imaging findings as well as *** SUMMARY The patients did not have cancer-related personal and family *** 1(a 49-year-old woman)was diagnosed with a bilateral breast nodule in May 2018 and was followed(preoperative imaging data including ultrasound and mammography)for 3 years;she underwent an excisional biopsy to address an enlargement in nodule *** 2(a 37-year-old woman)was diagnosed with a left breast nodule in June 2021 and consequently received vacuum-assisted biopsy of the tumor which appeared as“irregularly shaped”and“unevenly textured”tissue on *** pathological diagnosis was clear in both *** patients underwent breast-conserving surgery and sentinel lymph node *** two cases received or planned to receive radiotherapy as well as endocrine therapy(tamoxifen).CONCLUSION Breast DCIS arising within a fibroadenoma is rare,but patients treated with radiotherapy and endocrine therapy can have good prognosis.

关键词： Fibroadenoma ductal carcinoma in situ Vacuum-assisted biopsy Excisional biopsy Case report

Clinicopathological characteristics,treatments,and prognosis of breast ductal carcinoma in situ with microinvasion:A narrative review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chronic Diseases and Translational Medicine 2023年第1期9卷 5-13页

作者： Ge Song Yongqiang Zhang Department of Oncology Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical SciencesBeijingChina 2Graduate School of Peking Union Medical CollegeChinese Academy of Medical SciencesBeijingChina

Background:ductal carcinoma in situ with microinvasion(DCIS-MI)is defined as ductal carcinoma in situ(DCIS)with a microscopic invasive focus≤1 mm in the longest *** current literature is controversial concerning the clinical prognostic features and management of *** narrative review described recently reported literature regarding the characteristics,treatment,and prognosis of ***:Searching PubMed for relevant articles covering the period of 1982 to 2021 using the following terms by MeSH and free-word:breast cancer,microinvasion,DCIS,DCIS-MI,and invasive ductal carcinoma(IDC).Results:DCIS-MI tends to express more aggressive pathological features such as necrosis,HER2+,ER-or PR-,and high nuclear *** overall prognosis of DCIS-MI is typically good,however,some indicators such as young age,HR-,HER2+and multimicroinvasive lesions,were associated with worse *** there are also conflicting results on the differences between the prognoses of DCIS-MI and DCIS or *** chemotherapy and anti-HER2 therapy still have uncertain benefits and are more likely to be used to treat high-risk patients who are HR-orHER2+to improve the ***:DCIS-MI has more aggressive pathological features,which may suggest its biological behavior is worse than that of DCIS and similar to early *** the overall prognosis of DCIS-MI is good,when making decisions about adjuvant therapy clinicians need to give priority to the hormone receptor status,HER2 expression and axillary lymph node status of patients,because these may affect the prognosis and treatment response.

关键词： breast cancer ductal carcinoma in situ microinvasion pathological features treatment

Prognostic signifi cance of transcription factors FOXA1 and GATA-3 in ductal carcinoma in situ in terms of recurrence and estrogen receptor status

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Journal of Cancer Metastasis and Treatment 2015年第1期1卷 84-89页

作者： Mamatha Chivukula Jennifer Picarsic Gautam Bulusu Adam Brufsky Gretchen Ahrendt Gloria Carter Department of Pathology Mills-Peninsula Helath ServicesDorothy Schneider Breast Cancer CenterBurlingameCA 94050USA Department of Pathology Magee-Women’s Hospital of UPMCPittsburghPA 15213USA Department of Oncology University of Pittsburgh Cancer InstitutePittsburghPA 15232USA Department of Surgery Magee-Women’s Hospital of UPMCPittsburghPA 15213USA.

Aim:The aim was to analyze the expression of novel biological transcription markers,forkhead-box A1(FOXA1),GATA binding protein 3(GATA-3),and established markers such as Ki-67(MIB-1)and human epidermal growth factor receptor 2(HER2)in estrogen receptor(ER(+))and ER(-)ductal carcinoma in situ(DCIS)patients with/without ***:Two hundred and ninety-one cases of DCIS were retrieved from our pathology database,with complete data available for 219 *** follow-up period is from 1988 to *** is defined in terms of DCIS or invasive carcinoma(IC).No recurrence was seen in 88%(196/219)of cases;12%(26/219)had a recurrence(IC:13,DCIS:13).We are reporting the results of biological marker expression in terms of recurrence and ER ***:Our study demonstrates strong expression of GATA-3 in the ER(+)DCIS in recurrence and nonrecurrence groups similar to previously described in IC.A reduced expression of GATA-3 was observed in ER(-)recurrence and nonrecurrence groups.A strong HER2 protein expression,as well as high proliferation index,was seen in recurrence group(DCIS and IC).FOXA1 expression is reduced across the groups though not statistically signifi ***:This is the first study to analyze novel transcription markers FOXA1 and GATA-3 in *** work needs to be done on a larger cohort of DCIS cases with recurrence to better understand,which variables are best able to predict recurrence and guide therapy decision *** of FOXA1 and GATA-3 expression in ER(-)DCIS may offer new promising targets for therapy in future.

关键词： ductal carcinoma in situ estrogen receptor forkhead-box A1 GATA binding protein 3

The Impact of Ethnicity on the Incidence, Tumor Characteristics and Treatment of ductal carcinoma in situ—An 11-Year Clinical Experience at a High Volume Teaching Hospital

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Surgical Science 2016年第8期7卷 348-356页

作者： Lauren S. Sparber Vijayashree Murthy Ronald S. Chamberlain Department of Surgery Saint Barnabas Medical Center Livingston NJ USA Department of Surgery New Jersey Medical School Rutgers University Newark NJ USA Saint George’s University School of Medicine Grenada West Indies

Introduction: Screening mammography has led to a marked increase in detection of in situ breast tumors in the United States. The University of Southern California/Van Nuys Prognostic Index (USC/VNPI) predicts the recurrence rates of ductal carcinoma in situ (DCIS);however variations in tumor characteristics, USC/VNPI scores, receptor and human epithelial growth factor receptor (HER)-2/neu status across different ethnicities/races have not been well studied. This study aimed to evaluate the racial trends in incidence, patient demographics, tumor characteristics and treatment variations for patients with DCIS at a high volume teaching hospital. Methods: 395 women underwent surgical intervention for DCIS between 2000 and 2011. Their race/ethnicity was divided into five mutually exclusive categories and demographic and clinicopathological data was collected. Multivariate analysis was performed to evaluate variations in patient and tumor factors with respect to age, size and surgical management among different ethnicities and races. Results: 82.1% of Caucasian women underwent simple mastectomy with sentinel lymph node biopsy (SLNB) while lumpectomy with SLNB was highest in Hispanics (40%, p = 0.005). Overall, there was no significant difference in the incidence of receptor or HER-2/neu positivity, multicentricity, necrosis or grade of DCIS in the various racial groups, but there was a significant racial difference in the USC/VNPI scores (p < 0.001). Conclusion: On a community level, screening detected DCIS accounted for the vast majority of DCIS diagnosed, which reflected national trends. Although no racial variation in DCIS with respect to patient or tumor characteristics was observed, a racial difference in USC/VNPI score was identified among the Hispanic population. Additional studies are required to validate the significance of these findings.

关键词： ductal carcinoma in situ HER-2/Neu Ethnicity Race Breast Neoplasms

Detection and Clinical Significance of Peripheral Blood CTC, CA125, CA153, and CEA Levels in Patients with ductal carcinoma in situ

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Proceedings of Anticancer Research 2023年第5期7卷 89-94页

作者： Jirui Sun Qiushuang Ma Hong Chen Xing Zhou Jinku Zhang Baoding First Central Hospital Baoding 071000Hebei ProvinceChina

Objective:To explore the detection and clinical significance of peripheral blood CTC,CA125,CA153,and CEA levels in patients with ***:210 patients who received surgical treatment for breast cancer in our hospital from January 2019 to December 2022 were selected as the research *** to the postoperative pathology,100 cases were divided into breast cancer and 110 benign breast tumor *** hundred ten healthy patients undergoing physical examination during the same period were selected as the control ***153,CA125,and CEA levels were observed in the three ***:The levels of CA153,CA125,and CEA in the breast cancer group were significantly higher than those in the benign breast tumor group and the control group(P<0.05);the levels of CA153,CA125,and CEA in the benign breast tumor group were all higher than those in the control group,but the differences were not statistically significant;among the three tumor markers,CA153 has the highest sensitivity at 39.00%,CA125 has the second highest sensitivity at 18.00%,and CEA has the lowest sensitivity at 17.00%;The sensitivity of the two joint tests of CA153+CA125,CA153+CEA,and CA125+CEA for the diagnosis of breast cancer were 50.00%,48.00%,and 26.00%respectively;the sensitivity of the three joint tests is the highest,reaching 53.00%,while the specificity of the joint tests was lower than the individual ***:Detection of peripheral blood CTC,CA125,CA153,and CEA levels has specific reference significance for the treatment and prognosis of DCIS patients.

关键词： ductal carcinoma in situ CTC CA125 CA153

Serum semaphorin 4C as a diagnostic biomarker in breast cancer:A multicenter retrospective study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2021年第12期41卷 1373-1386页

作者： Ya Wang Long Qiao Jie Yang Xiong Li Yaqi Duan Jiahao Liu Shaoqi Chen Huayi Li Dan Liu Tian Fang Jingjing Ma Xiaoting Li Fei Ye Junxiang Wan Juncheng Wei Qin Xu Ensong Guo Ping Jin Mingfu Wu Lin Zhang Yun Xia Yaqun Wu Jun Shao Yaojun Feng Qing Zhang Zongyuan Yang Gang Chen Qinghua Zhang Xingrui Li Shixuan Wang Junbo Hu Xiaoyun Wang Mona P.Tan Kazuaki Takabe Beihua Kong Qifeng Yang Ding Ma Qinglei Gao Department of Obstetrics and Gynecology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030P.R.China Cancer Biology Research Center(Key Laboratory of the Ministry of Education) Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030P.R.China Department of Obstetrics and Gynecology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450000P.R.China Department of Gynecology and Obstetrics The Central Hospital of WuhanTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430014P.R.China Department of Pathology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030P.R.China Department of Obstetrics and Gynecology Wuhan Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430022P.R.China Department of Neurosurgery Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030P.R.China Leonard Davis School of Gerontology University of Southern CaliforniaLos AngelesCalifornia 90001USA Department of Thyroid and Breast Surgery Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030P.R.China Department of Breast Surgery Hubei Cancer HospitalWuhanHubei 430079P.R.China Department of Gynecology and Obstetrics Qilu Hospital of Shandong UniversityJinanShandong 250012P.R.China Yidu Cloud(Beijing)Technology Co. Beijing 100000P.R.China MammoCare The Breast Clinic&SurgerySingapore 329563Singapore Department of Surgery and the Massey Cancer Centre Virginia Commonwealth University School of MedicineRichmondVirginia 23298USA Department of Breast Surgery Qilu Hospital of Shandong UniversityNo.107Jinan Culture RoadJinanShandong 250012P.R.China

Background:To date,there is no approved blood-based biomarker for breast cancer ***,we aimed to assess semaphorin 4C(SEMA4C),a pivotal protein involved in breast cancer progression,as a serum diagnostic ***:We included 6,213 consecutive inpatients from Tongji Hospital,Qilu Hospital,and Hubei Cancer *** cohort and two validation cohorts were introduced for diagnostic exploration and validation.A pan-cancer cohort was used to independently explore the diagnostic potential of SEMA4C among solid *** cancer patients who underwent mass excision prior to modified radical mastectomy were also *** hypothesized that increased pretreatment serum SEMA4C levels,measured using optimized in-house enzymelinked immunosorbent assay kits,could detect breast *** endpoints were diagnostic performance,including area under the receiver operating characteristic curve(AUC),sensitivity,and ***-surgery pathological diagnosis was the reference standard and breast cancer staging followed the TNM *** was no restriction on disease stage for ***:We included 2667 inpatients with breast lesions,2378 patients with other solid tumors,and 1168 healthy ***,118 patients with breast cancer were diagnosed with stage 0(5.71%),620 with stage I(30.00%),966 with stage II(46.73%),217 with stage III(10.50%),and 8 with stage IV(0.39%).Patients with breast cancer had significantly higher serum SEMA4C levels than benign breast tumor patients and normal controls(Pductal carcinoma in situ(n=85)were 0.931(95%CI:0.916–0.946)and 0.879(95%CI:0.832–0.925),*** SEMA4C levels significantly decreased after surgery,and the reduction was more str

关键词： breast cancer semaphorin 4C serum biomarker diagnosis early detection ductal carcinoma in situ pan-cancer analysis enzyme-linked immunosorbent assay

Clonal Analysis of Peripheral Papilloma and Cancerous Cells of the Breast

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Clinical Oncology 2007年第6期4卷 401-404页

作者： Qi Yu Yun Niu Yong Yu Xiumin Ding Yurong Shi Key Laboratory of Breast Cancer Prevention and Therapy Tianjin Medical UniversityMinistry of Education Tianjin 300060 China.China Jinghai Hospital Jinghai 301600 TianjinChina

OBJECTIVE Because almost all malignancies represent monoclonal proliferations, we have studied the clonal status of peripheral papillomas （peri-PM）, ductal carcinomas in situ （DCIS）, and normal breast tissues to explore a reliable way to distinguish benign and malignant （or pre-malignant） cases previously diagnosed morphologically. METHODS Twenty-six cases of peri-PM, 25 cases of peri-PM with atypical ductal hyperplasia （ADH）, 27 cases of DCIS, 16 cases of developed canceration and 20 specimens of normal tissue were examined in the study. The clonal status of these tissues was studied using an assay based on inactivation mosaicism of the lenth-polymorphic X-chromosomes at the androgen receptor （AR） locus. RESULTS Loss of polymorphism at the AR locus was found in all DCIS cases and 10 cases （10/25, 40.0%） of peri-PM with ADH, *** the monoclonality of the tumors. Twenty-four out of 26 （92.3%） cases with peri- PM and 19 specimens of normal tissue were shown to be polyclonal. In 16 cases of developed Canceration, identical X chromosome inactivation （monoclonal alterations） was observed from both the peri-PM with ADH part, and the DCIS part in each Case. CONCLUSION These results contribute to the understanding of the genetic changes of peri-PM, and confirm the peri-PM with ADH as a precancerous lesion of the breast. Clonal analysis might be a useful modality to screen high-risk cases from precancerous lesions or to distinguish between benign hyperplasia and early carcinoma.

关键词： peripheral papilloma of the breast precancerous lesion ductal carcinoma in situ clonal analysis androgen receptor.

Low-Grade and High-Grade Invasive ductal carcinomas of the Breast Follow Divergent routes of Progression

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Clinical oncology and cancer researeh 2011年第3期8卷 123-127页

作者： Yun NIU Key Laboratory of Breast Cancer Prevention and Therapy Tianjin Medical University Ministry of Education and Key Laboratory of Cancer Prevention and Therapy of Tianjin Tianjin Medical University Cancer Institute and Hospital West Huanhu Road Ti Yuan Bei Hexi District Tianjin 300060 China

Low-grade invasive ductal carcinoma is almost diploid, and has frequent losses of chromosome 16q, which is shared by other precancerous lesions of the mammary gland such as flat epithelial atypia （FEA）, atypical ductal hyperplasia （ADH）, and lownuclear grade ductal carcinoma in situ （DCIS）. The genetic alterations accumulate in a stepwise fashion as the precancerous lesions progress to invasve ductal carcinoma. This supports the linear progression model of breast cancer from FEA, through ADH, to low- nuclear grade DCIS as non-obligate early events in low-grade IDC evolution. In contrast, high-grade carcinoma tends to aneuploidy with complex genetic alterations--most importantly, frequent gains at chromosome 16q. Frequent losses at chromosome 16q in low-grade IDC and gains in the same arm of the same chromosome in high-grade IDC imply that these lesions are two end outcomes of different disease processes and that they do not lie in the same continuum of a process. Therefore, low-grade and high-grade IDC are two distinct diseases with a divergent route of progression.

关键词： flat epithelial atypia atypical ductal hyperplasia ductal carcinoma in situ invasive ductal carcinoma histologic grade breast cancer progression

Axillary Recurrences after Sentinel Node Surgery—Results over Ten Years in a University Hospital

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2012年第5期3卷 846-852页

作者： Helle Eilertsen Ellen Schlichting Marianne Efskind Harr Daehoon Park Torill Sauer Siri Laronningen Rolf Kaaresen Medical Faculty University of OsloOsloNorway Department of Breast and Endocrine Surgery Oslo University HospitalOsloNorway Department of Neurosurgery Oslo University HospitalOsloNorway Department of Pathology Vestre Viken HospitalDrammenNorway Department of Pathology Oslo University HospitalOsloNorway Cancer Registry of Norway OsloNorway.

Background: Sentinel node biopsy (SNB) was introduced at Ullevaal University Hospital in 2000. This article presents results from the first ten years use of the method. Material and Methods: A prospective registration of 2762 patients was made from 2000 through 2009. Results: The median follow-up time was 51 months. The overall detection rate was 93%. 36% of the patients with positive SNs had non-sentinel metastases. These were significantly associated with a macrometastatic SN and a primary tumour>20 mm. 18% of patients with sentinel metastasis≤2 mm had non-sentinel metastases. 14 patients with negative SN (0.7%) developed axillary recurrence. 32% with a preoperative diagnosis of ductal carcinoma in situ (DCIS) were upstaged to infiltrating carcinoma on final histology. None of the patients with pure DCIS had positive SNs. Conclusion: Few late events (0.7%) in SN negative axillas demonstrate the safety of the technique.

关键词： Breast Cancer ductal carcinoma in situ Sentinel Node Non-Sentinel Metastasis Axillary Recurrence